2020089-41-0
Chemical Structure
(Rac)-Lartesertib
Synonym(s): (Rac)-M4076;(Rac)-ATM Inhibitor-5
- CAS No.: 2020089-41-0
- Formula:C23H21FN6O3
- Molecular Weight:448.45
IUPAC Name: 8-(1,3-dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
InChIKey: WNEFOSMCGCLLJU-UHFFFAOYSA-N
SMILES: O=C1N(C2=C(N1C)C=NC3=C2C=C(C4=CN(C)N=C4C)C(OC)=C3)C5=C(OC)C=NC=C5F
Biological Activity: (Rac)-Lartesertib ((Rac)-M4076) is an isoform of Lartesertib (HY-150617). Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(Rac)-Lartesertib | (Rac)-Lartesertib ((Rac)-M4076) is an isoform of Lartesertib (HY-150617). Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mukker J K, et al. In vitro evaluation of myelosuppressive effects of ATRi tuvusertib and ATMi lartesertib (M4076), alone and in combination. Cancer Research, 2024, 84(6_Supplement): 7186-7186.
- [2]. Laaber K, et al. Combined inhibition of ATR and ATM with tuvusertib and lartesertib (M4076) impacts the tumor microenvironment. Cancer Research, 2024, 84(6_Supplement): 5617-5617.
